01541.HK_Providing professional financial news and data related to 01541.HK, committed to creating a comprehensive and efficient information access channel for users | NewTimeSpace

IMMUNEONCO-B (01541.HK): First patient dosed in Phase II trial of IMM2510 plus IMM27M as first-line treatment for advanced HCC

Tags：

IMMUNEONCO-B 01541.HK Clinical Trial

2026-08-27

IMMUNEONCO-B (01541.HK): First patient dosed in IMC-003 PAH trial, SAD and MAD dose cohorts fully enrolled

Tags：

IMMUNEONCO-B 01541.HK R&D Progress

2026-08-25

IMMUNEONCO-B (01541.HK): Subsidiary Yiming Kaier receives RMB 50 million capital increase from Shengke Qihang and other investors; Company to hold approximately 68.34% upon completion

Tags：

IMMUNEONCO-B 01541.HK

2026-08-07

IMMUNEONCO-B (01541.HK): First Patient Dosed in Phase II/III Trial of IMM0306 for IgG4-Related Disease

Tags：

IMMUNEONCO-B 01541.HK first patient dosing

2026-07-10

Scan QR Code

Download App